Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity

被引:0
|
作者
Klivenyi, P
Beal, MF
Ferrante, RJ
Andreassen, OA
Wermer, M
Chin, MR
Bonventre, JV
机构
[1] Massachusetts Gen Hosp, Serv Neurol, Neurochem Lab, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA
[4] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA
[5] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA
[6] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA
[7] Dept Vet Affairs, Bedford, MA USA
关键词
MPTP; free radicals; arachidonic acid; phospholipase; Parkinson's disease;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Phospholipase A, (PLA,) enzymes are critical regulators of prostaglandin and leukotriene synthesis, and they may also play an important role in the generation of intracellular free radicals. The group IV cytosolic form of phospholipase A, (cPLA(2)) is regulated by changes in intracellular calcium concentration, and the enzyme preferentially acts to release arachidonic acid esterified at the sn-2 position of phospholipids. We examined the susceptibility of mice carrying a targeted mutation of the cPLA(2) gene to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. Mutant mice have no functional cPLA2 activity. Mice that were homozygous for the mutation (cPLA(2)(-/-)) were significantly resistant to MPTP-induced dopamine depletion as compared with littermate control (cPLA(2)(-/-)) and heterozygous mice (cPLA(2)(+/-)). These findings provide evidence that cPLA(2) plays a role in MPTP neurotoxicity and suggest that cPLA(2) may play a role in the development of Parkinson's disease in humans.
引用
收藏
页码:2634 / 2637
页数:4
相关论文
共 50 条
  • [32] Cloning and expression of a group IV cytosolic Ca2+-dependent phospholipase A2 from rat pancreatic islets.: Comparison of the expressed activity with that of an islet group VI cytosolic Ca2+-independent phospholipase A2
    Ma, ZM
    Ramanadham, S
    Hu, ZQ
    Turk, J
    BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1998, 1391 (03): : 384 - 400
  • [33] Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group v secreted phospholipase A2
    Six, David A.
    Barbayianni, Efrosini
    Loukas, Vassilios
    Constantinou-Kokotou, Violetta
    Hadjipavlou-Litina, Dimitra
    Stephens, Daren
    Wong, Alan C.
    Magrioti, Victoria
    Moutevelis-Minakakis, Panagiota
    Baker, Sharon F.
    Dennis, Edward A.
    Kokotos, George
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (17) : 4222 - 4235
  • [34] Overexpression and regulation of cytosolic phospholipase A2 group IVA in patients with asthma
    Sokolowska, M.
    Stefanska, J.
    Luczak, E.
    Wodz-Naskiewicz, K.
    Cieslak, M.
    Pawliczak, R.
    ALLERGY, 2010, 65 : 2 - 3
  • [35] Group IVC cytosolic phospholipase A2 γ is farnesylated and palmitoylated in mammalian cells
    Tucker, DE
    Stewart, A
    Nallan, L
    Bendale, P
    Ghomashchi, F
    Gelb, MH
    Leslie, CC
    JOURNAL OF LIPID RESEARCH, 2005, 46 (10) : 2122 - 2133
  • [36] Role for cytosolic phospholipase A2α in autoimmune diabetes in nonobese diabetic mice
    Oikawa, Y
    Yamato, E
    Tashiro, F
    Yamamoto, M
    Uozumi, N
    Shimada, A
    Shimizu, T
    Miyazaki, JI
    DIABETES, 2005, 54 : A308 - A308
  • [37] Roles for cytosolic phospholipase A2α as revealed by gene-targeted mice
    Uozumi, N
    Shimizu, T
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2002, 68-9 : 59 - 69
  • [38] Cytosolic phospholipase A2α interacts with microtubules
    Nakatani, Y
    Sunaga, S
    Murakami, M
    Kudo, I
    EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY, 5, 2002, 507 : 21 - 24
  • [39] Regulation of cytosolic phospholipase A2 translocation
    Evans, JH
    Fergus, DJ
    Leslie, CC
    ADVANCES IN ENZYME REGULATION, VOL 43, 2003, 43 : 229 - 244
  • [40] Human cytosolic phospholipase A2 inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 2000, 5 (07) : 301 - 302